SK Biopharm Epilepsy New Drug 'Cenobamate' Enters Latin American Market

Technology Licensing Agreement with Brazilian Pharmaceutical Company Europharma
Securing Markets in Four Continents Including North America, Europe, and Asia

[Asia Economy Reporter Lee Gwanju] SK Biopharm announced on the 14th that it has signed a technology export contract with Eurofarma to commercialize the innovative epilepsy drug 'Cenobamate' in the Latin American region.

The contract includes an upfront payment of $15 million, milestone payments of $47 million based on approvals and sales, and royalties from sales.

In May, SK Biopharm formed a partnership with Dexel Pharma to launch in Israel, opening the gateway to the West Asian market. With this new partnership, Cenobamate has now entered four continents: North America, Europe, Asia, and Latin America.

Eurofarma, responsible for the launch and sales of Cenobamate in Latin America, is a major pharmaceutical company headquartered in Brazil. It has expertise in sales and marketing of central nervous system therapeutics and possesses a sales network throughout Latin America.

Cenobamate will be sold in 17 Latin American countries, including Brazil and Mexico, through Eurofarma. It is known that more than half of the over 6 million epilepsy patients in Latin America do not receive adequate treatment. This technology export is expected to provide new treatment options for epilepsy patients in the Latin American region.

Jungwoo Cho, CEO of SK Biopharm, said, “We are pleased to provide innovative treatments to epilepsy patients in Latin America through our strategic alliance with Eurofarma. Having once again recognized the value of Cenobamate, we will accelerate the expansion of local partnerships to offer Cenobamate to many epilepsy patients worldwide.”

This content was produced with the assistance of AI translation services.